Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8785045 | Advances in Radiation Oncology | 2016 | 8 Pages |
Abstract
For patients with HN MCC, omission of PORT was associated with a significantly higher risk of local recurrence even among those patients with the lowest-risk tumors (i.e., Stage IA without immune suppression). Thus, it is important to weigh the benefits of PORT against the side effect profile on a case-specific basis for each patient.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Seesha R. BS, Tessa E. BS, Christopher BS, Erica S. MD, Ilsa D. Juhlin, Astrid MD, Jayasri G. MD, Jay J. MD, Yolanda D. MD MPhil, Teresa MD, Paul MD PhD, Upendra MBBS FRANZCR,